A 12-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease.

Trial Profile

A 12-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs Donepezil (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Eisai Medical Research
  • Most Recent Events

    • 31 Jul 2009 Additional lead trial centre identified as reported by United Kingdom Clinical Research Network record.
    • 04 Mar 2009 Identified and integrated new source (United Kingdom Clinical Research Network).
    • 23 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top